Brief: Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
29/12/2025 13:49
Dec 29 (Reuters) - Adlai Nortye Ltd ANL.O: ADLAI NORTYE ENTERS EXCLUSIVE LICENSE AGREEMENT WITH ASK PHARM FOR PAN-RAS (ON) INHIBITOR AN9025 IN GREATER CHINA ADLAI NORTYE LTD - ELIGIBLE FOR UP TO RMB 1.6 BILLION ADLAI NORTYE LTD - ASK PHARM OBTAINS EXCLUSIVE RIGHTS TO AN9025 IN GREATER CHINA Source text: ID:nGNX7wQ7LR Further company coverage: ANL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adlai Nortye
See all newsAdvisory: Alerts wrongly tagged to Merck & Co withdrawn
Brief: Adlai Nortye Appoints Christopher Liu, Pharmd, As Head Of Investor Relations And Public Relations
Brief: Adlai Nortye Announces Clinical Trial Notification Submission And Hrec Approval
Brief: Adlai Nortye Files For Mixed Shelf Offering Of Up To $600 Million
U.S. STOCKS ON THE MOVE-Netflix, J.B. Hunt, Arxis